IVIG: limited benefit in Alzheimer’s disease


Two recent studies have reported on the effects of intravenous immunoglobulin in patients with cognitive impairment due to Alzheimer’s disease.

The first study found a short-term benefit of IVIG in 50 subjects with mild cognitive impairment (MCI) due to AD (Kile et al. J Neurol Neurosurg Psychiatry 2017;88:106-112). Study participants were aged 50-84 years and had amnestic MCI.

It takes 30 seconds

Recommend to a Colleague

Related Posts

Go back to home page